Skip to content

Median Effective Dose of Ciprofol-Assisted Sedation for Elderly Patients Undergoing Knee Arthroplasty

Median Effective Dose of Ciprofol-Assisted Sedation for Elderly Patients Undergoing Knee Arthroplasty

Status
Completed
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06293131
Enrollment
70
Registered
2024-03-05
Start date
2023-05-29
Completion date
2023-09-28
Last updated
2024-03-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ED50, Knee Arthroplasty, Sedation

Brief summary

Regional anesthesia is a common clinical anesthesia method, and regional anesthesia-assisted sedation play a central role in promoting patient comfort and relieving anxiety. With increasing age, elderly people experience changes in pharmacokinetics and pharmacodynamics and increased drug sensitivity. Ciprofol has advantages in adverse events such as hypotension and respiratory depression. There are fewer studies on the recommended dosage of ciprofol-assisted sedation for intrathecal anesthesia in elderly patients. The aim of study is to identify the median effective dose(ED50) of ciprofol-assisted sedation in elderly patients undergoing spinal anesthesia

Detailed description

Select the patients who received knee arthroplasty in the Second Hospital of Shanxi Medical University. The patients received a loading dosage of 0.05mg/kg of ciprofol to begin sedation following the completion of intravertebral anesthesia, and the maintenance dose is calculated using the sequential method. Based on the relevant literature and pilot study, 0.2 mg·kg-1·h-1 is selected as initial test dose with a dose gradient of 0.02 mg·kg-1·h-1. The Modified Alertness Sedation Score (MOAA/S ) scores and the bispectral index (BIS) were recorded for patients before administration (T0), 5 min after administration (T1), 10 min after administration (T2), 20 min after administration (T3), 30 min after administration (T4), 45 min after administration (T5), and 60min after administration (T6). If the first patient had ≥ 4 time points with MOAA/A score ≤3 and BIS\<85 from T0-T6, the sedation was regarded as satisfactory, then the next patient 's dose of ciprofol was reduced by one level. On the contrary, if the patient's MOAA/S score and BIS at T0-T6 had less than 4 points of MOAA/S ≤3 points and BIS \<85, it was regarded as unsatisfactory sedation. The next patient's dose of ciprofol was increased by one level. After 8 crossovers, the trial was terminated. At the same time, the change of vital signs and adverse reactions before and after administration were recorded

Interventions

DRUGCiprofol

Ciprofol was injected intravenously, and was pumped during operation to maintain sedation

Sponsors

Second Hospital of Shanxi Medical University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥ 65 years * ASA grade I\ III * BMI 18\ 30 kg/m2

Exclusion criteria

* Contraindications to intrathecal anesthesia * Suffering from severe psychiatric or neurologic disorders or taking sedative drugs within the last 3 months * Difficult airway or having respiratory diseases such as upper airway obstruction * Severe cardiovascular system diseases * Severe hepatic or renal dysfunction * Allergy or contraindication to propofol and its drug-related components * Patient Prefusal

Design outcomes

Primary

MeasureTime frameDescription
Bispectral index (BIS)24 hoursChanges in Bispectral index
Modified Alertness Sedation Score (MOAA/S)24 hoursChanges in Modified Alertness Sedation Score

Secondary

MeasureTime frameDescription
diastolic blood pressure(DBP)24 hoursChanges in diastolic blood pressure
pulse oxygen saturation(SpO2)24 hourschanges in pulse oxygen saturation
heart rate (HR)24 hourschanges in heart rate
systolic blood pressure (SBP)24 hoursChanges in systolic blood pressure

Other

MeasureTime frameDescription
Occurrence of Sedation-related adverse events72 hoursIt includes intraoperative and postoperative sedation-related adverse events

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026